300705 九典制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.12018.23622.77220.88920.340
总资产报酬率 ROA (%)1.39412.79316.41114.24413.335
投入资产回报率 ROIC (%)1.66915.18319.26916.68915.446

边际利润分析
销售毛利率 (%)66.84572.94473.23577.15177.776
营业利润率 (%)10.26517.28619.61914.64712.523
息税前利润/营业总收入 (%)11.35617.33119.98715.16013.071
净利润/营业总收入 (%)9.11615.10917.48313.67711.594

收益指标分析
经营活动净收益/利润总额(%)89.509100.87491.32093.87397.379
价值变动净收益/利润总额(%)-0.731-0.1820.5440.5300.635
营业外收支净额/利润总额(%)-0.122-2.162-0.4881.937-0.375

偿债能力分析
流动比率 (X)3.7313.6444.0883.4412.715
速动比率 (X)2.8132.8143.1492.8022.173
资产负债率 (%)31.03430.67125.09231.27432.486
带息债务/全部投入资本 (%)11.70310.2136.97512.59418.160
股东权益/带息债务 (%)665.589779.6461,253.878645.054430.872
股东权益/负债合计 (%)210.661215.709298.526219.758207.823
利息保障倍数 (X)10.29142.17743.23267.80421.978

营运能力分析
应收账款周转天数 (天)45.55438.01555.03667.10454.711
存货周转天数 (天)166.676153.631145.312148.212158.600